stockchase picture

Compiling comments that experts make about stocks while on public TV.

There are 2 registered members and 127 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 37.5100 on 2013-06-19 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2008-11-21 TOP PICK Walter Gerasimowicz Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
 Price:
$51.520
Subject:
US & GLOBAL LARGE CAP
Bias:
UNKNOWN
Owned:
Yes
2011-10-19 HOLD Stan Wong The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
Price:
$53.250
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
DEFENSIVE
Owned:
No
2012-04-19 BUY Stan Wong This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
 Price:
$59.510
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
CAUTIOUS
Owned:
No
2013-03-07 BUY Patrick Horan

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.

 Price:
$34.430
Subject:
NORTH AMERICAN
Bias:
BULL
Owned:
Yes
2007-08-29 BUY Norman Levine In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
 Price:
$51.490
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
2011-10-24 COMMENT Norman Levine Likes health care companies generally because they’re defensive. Splitting their drug company from the rest of the company. Likes this as you get pure plays.
 Price:
$53.450
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
No
2011-11-29 BUY on WEAKNESS Norman Levine Fundamentally he likes it. Operationally it is performing as it should. They are tied into the European economy and people are worried about the EU economies, although their sales are holding up. Getting hurt by tax-loss selling.
 Price:
$53.050
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
2001-01-08 BUY Noah Blackstein, B.A., CFA Getting into acquisitions. Had to restructure. Moving from a value to a growth stock
 Price:
$42.563
Subject:
US & GLOBAL LARGE CAP
Bias:
BULL
Owned:
Unknown
2012-11-19 TOP PICK Mohsin Bashir

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

 Price:
$62.920
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2013-02-05 COMMENT John O'Connell, CFA

(Market Call Minute.) There is a spinoff coming on a restructuring, so be careful about tax implications. When it spins off, buy the medical device manufacturer.

 Price:
$33.840
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Unknown
2012-09-25 HOLD Jeff Black

Great quality company. They are splitting their medical devices and pharmaceuticals but if you own, stay the course. Likes the space. Have executed well.

 Price:
$69.570
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
BEARISH
Owned:
Yes
2004-05-21 TOP PICK Harvey Eisen Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
 Price:
$40.000
Subject:
NOT APPLICABLE
Bias:
OPTIMISTIC
Owned:
Yes
2010-11-19 BUY on WEAKNESS Hap (Robert) Sneddon FCSI Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
 Price:
$47.400
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
UNKNOWN
Owned:
No
2012-09-04 TOP PICK Hap (Robert) Sneddon FCSI

Has got a really good pipeline and well owned by institutions.  Great triple A balance sheet and a good yield.  Screens well against S&P stocks.  Slight sideways action.  Company will be splitting into two components in the future.  This will unlock value.

 Price:
$65.460
Subject:
TECHNICAL ANALYSIS
Bias:
CAUTIOUS
Owned:
Yes
2009-07-08 BUY Gordon Reid Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
 Price:
$46.310
Subject:
US EQUITIES
Bias:
CAUTIOUSLY OPTIMISTIC
Owned:
No
Showing 1 to 15 of 62 entries
First Previous 1 2 3 4 5 Next Last

No Comments.

You must be logged in to comment.